Table of Contents
ISRN Neurology
Volume 2014 (2014), Article ID 861091, 4 pages
http://dx.doi.org/10.1155/2014/861091
Research Article

Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait

1Division of Neurology, Department of Medicine, Amiri Hospital, Arabian Gulf Street, 13041 Kuwait City, Kuwait
2Neurology Clinic, Dasman Diabetes Institute, P.O. Box 1180, 15462 Dasman, Kuwait

Received 3 October 2013; Accepted 20 November 2013; Published 22 January 2014

Academic Editors: A. Karni, Y. Ohyagi, and W. Zhao

Copyright © 2014 S. Lamdhade et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. Multiple sclerosis (MS) therapeutics entered a new era after the development of anti-JC virus (anti-JCV) antibody assay that assesses the risk of development of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab. Objective. To determine the prevalence of anti-JCV antibody among MS patients in Kuwait. Methods. Using the national MS registry, demographics and disease characteristics of MS patients who were screened for anti-JC virus antibody were collected. The prevalence of anti-JCV antibody seropositivity and its association with demographic and disease characteristics were evaluated. Results. Out of 110 screened MS patients for anti-JCV antibodies, 65.5% were females. Mean age and disease duration were 29.23 ± 8.55 and 5.39 ± 5.04 years, respectively. 47.3% of patients were already on natalizumab and 52.7% of patients were screened for stratification to either natalizumab or a different Disease Modifying Therapy (DMT). The overall prevalence of anti-JC virus antibody was 40%. Gender ( ), disease duration ( ), and number of natalizumab infusions ( ) were not associated with seropositivity. Patients aged ≥30 years were more likely to be seropositive ( ). Conclusion. The prevalence of anti-JCV antibody is slightly lower than what is reported in published studies. Seropositivity was associated with an increasing age of MS patients.